Mumbai, Indien (ots/PRNewswire) – – The work will be carried out at the Piramal Pharma Solutions development and manufacturing facility in Lexington, Kentucky
– MSA covers work on Plus Therapeutics’ RNL-liposome intermediate
Piramal Pharma Limited’s (PPL) Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions (PPS), announced today that it has entered into a Master Services Agreement (MSA) with Plus Therapeutics, Inc. that will provide Piramal the Enables the provision of services related to the development, manufacture and supply of Plus Therapeutics’ RNL liposome intermediate.
The MSA includes the transfer of analytical methods, the development of microbiological methods, process transfer and optimization, the manufacture of drug intermediates and stability studies. The transfer will be made at PPS’s drug manufacturing facility in Lexington, Kentucky. The two companies envision that the MSA will result in clinical and commercial supply agreements for the drug product at the appropriate stage of development.
PPS’s Lexington facility is recognized as the North American leader in the formulation, development and manufacture of sterile parenteral drug products. The Lexington facility is able to support drug development for New Chemical Entities (NCEs), generics, and molecules that may be eligible for 505 (b) (2) approval.
Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited, stated, “We are excited to partner with Plus Therapeutics. We believe this is the beginning of a long, collaborative, mutually beneficial relationship that has our ultimate goal of reducing the burden of disease on patients.”
“This agreement marks another important milestone for Plus as we work to advance the development of RNL as a novel treatment option for patients with glioblastoma,” said Marc Hedrick MD, President and Chief Executive Officer of Plus Therapeutics. “The PPS team has the knowledge, experience and expertise to support our needs, both now and in the future, as we drive RNL toward approval.”
Information on Piramal Pharma Solutions:
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) that offers end-to-end development and manufacturing solutions across the entire life cycle of pharmaceuticals. We serve our customers through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a full range of services including drug discovery solutions, process and pharmaceutical development services, clinical investigational medicinal products, commercial delivery of active pharmaceutical ingredients and finished dosage forms. We also provide specialized services such as the development and manufacture of high potency APIs and antibody-drug conjugation, sterile filling / completion with and without containment, and potent solid oral drugs. Our capabilities as an integrated service provider and our experience with various technologies enable us to supply innovators and generic manufacturers worldwide.
For more information, please visit the following website: www.piramalpharmasolutions.com | Social media: Twitter, LinkedIn
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities in 14 global facilities and a global distribution network in over 100 countries. PPL includes: Piramal Pharma Solutions, an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care, a complex hospital generic business; and the Consumer Healthcare business, which sells over-the-counter products in India. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulation market. In October 2020, PPL received 20% strategic growth investments from the Carlyle Group.
More information can be found on the following website: www.piramal.com | Social Media: Facebook, Twitter, LinkedIn
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-phase pharmaceutical company whose radiotherapeutic portfolio focuses on nanoliposomal encapsulated radionuclides for a variety of cancer targets. At the heart of the company’s drug development is a unique nanotechnology platform for reformulating, delivering, and commercializing multiple drugs for rare cancers and other diseases. The platform is designed to enable new delivery approaches and / or formulations of safe and effective injectable drugs that can improve safety, efficacy and convenience for patients and healthcare providers. More information is available at PlusTherapeutics.com and ReSPECT-Trials.com.
Logo – https://mma.prnewswire.com/media/1425672/Piramal_Pharma_Solutions_Logo.jpg
For Piramal Pharma media inquiries:
Dimple Kapur / Niyati Vora
Dimple.Kapur@piramal.com / Niyati.email@example.com
For Piramal Pharma investors
Hitesh Dhaddha / Mayank Kumar
Investor Relations firstname.lastname@example.org
[ source link ]
Piramal Pharma Solutions entered framework service agreement Therapeutics